Professional Ad Report

Pro ad report: All the data on journal spending in 1H 2016

Pro ad report: All the data on journal spending in 1H 2016

By

Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.

Professional Ad Report: Staying Power

Professional Ad Report: Staying Power

By

Print has been written off so often as being obsolete and unwieldy that it seems a wonder that it is still with us. So why does Kantar Media data for the first half of 2015 suggest that print remains vital? Rebecca Mayer Knutsen breaks down the numbers—and through the conventional wisdom

Journal Ad Review: Back in the Mix

Journal Ad Review: Back in the Mix

By

A few years ago medical publishers were approaching a cliff and the choices were simple: Evolve the business or fall over the edge. By having learned to survive, some publishers are now ready to thrive

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

By

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what 2014's slight uptick means in the context of an evolving media mix

Journal Ad Review: Paper Chase

Journal Ad Review: Paper Chase

By

The downward spiral for journals continues. Is anyone surprised? Larry Dobrow on how the fundamental shift to digital continued to affect professional media last year, including the full-year numbers by advertisers and brands

Professional Ad Report: Spinal Trap

Professional Ad Report: Spinal Trap

By

No one expected the numbers to be pretty. And medical/surgical journals' latest losses weren't. Larry Dobrow analyzes the numbers for the first half of 2013 by advertisers and brands

Journal Ad Report 2012: In a Bind

Journal Ad Report 2012: In a Bind

By

Pharma's turn to specialty drugs hasn't been good for print. Ad pages in medical/surgical journals fell steeply in 2012, despite the pickup in FDA approvals. Larry Dobrow reports the full-year numbers

Journal Ad Review: Pulp Friction

Journal Ad Review: Pulp Friction

By

Ad spend for medical/surgical journals declined by 16.5%, as patent expiries and regulatory delays stifled 2011's comeback bid. Marc Iskowitz reports on the numbers for the first half of 2012

Journal Ad Review 2011: On a Tear

Journal Ad Review 2011: On a Tear

By

Medical/surgical journal advertising grew in 2011, the second consecutive year it's been in the black. Marc Iskowitz on which categories and brands attracted the most advertising dollars

OPINION

Email Newsletters